Pseudomonas aeruginosa alkaline protease (AP) has recently been shown to produce limited proteolysis of human gamma interferon (IFN--y) and thereby destroy the antiviral and macrophage-activating activities of the lymphokine. In the present study we describe some of the characteristics of Pseudomonas elastase (E) with regard to inactivation of human IFN-,y. The inhibitory effect of E on IFN--y bioactivity differed from that of AP in that the direct effects of E were reduced in the presence of human serum. That this property of human serum was in large part attributable to the protease inhibitor a2-macroglobulin (%2-M) was suggested by the following observations: (i) methylamine treatment of serum reduced its effect on E, (ii) E interacted directly with OL2-M to induce a characteristic conformational change in the protease inhibitor, and (iii) preformed E-a2-M complexes lacked IFN-y-degrading activity. Despite these findings, anti-E antiserum partially neutralized the effect that a Pseudomonas filtrate showed on IFN--y, suggesting that E contributes to the activity of bacterial filtrates. Treatment of IFN--y with E in the presence of a suboptimal concentration of AP resulted in an E dose-dependent inactivation of the lymphokine. Preformed E-_2-M complexes, although ineffective by themselves at cleaving IFN-y, degraded the lymphokine, providing AP was also present in the reaction mixture.
These data demonstrate that the destruction of small, biologically significant peptides by Pseudomonas proteases can involve protease-protease synergy that acts even in the presence of the serum protease inhibitor
A number of studies have shown that the opportunistic pathogen Pseudomonas aeruginosa can nonspecifically inhibit T-lymphocyte-mediated immunity in vitro (14, 15, 26, 32, 36) and in vivo (5, 14, 30) . Patients infected with P. aeruginosa often show evidence of impaired cell-mediated immunity (28, 33, 34) . In support of these clinical findings, Neely et al. (25) demonstrated that infection with P. aeruginosa predisposed burned mice to lethal infections with Candida albicans. Two independent groups, Blackwood et al. (5) and Petit et al. (30) , found that mice injected with P. aeruginosa were more susceptible to infection with the intracellular pathogen Listeria monocytogenes and showed a decrease in delayed-type hypersensitivity to Listeria and erythrocyte antigens.
Gamma interferon (IFN-y) is a T-cell-derived lymphokine with potent antiviral activity that undoubtedly plays an important role in cell-mediated immunity. We recently observed that the Pseudomonas exoenzyme alkaline protease (AP) reduced the antiviral and immunomodulatory activities of human IFN--y by limited proteolytic degradation of the lymphokine (15) . Thus, AP caused a minor reduction in the mass of IFN--y, which resulted in a significant decline in the bioactivity of the lymphokine. These findings provide a plausible explanation for some of the observations cited above regarding the immunosuppressive properties of P. aeruginosa and suggest a general mechanism whereby pathogenic microorganisms may interfere with host immune responses.
Since many clinical isolates of P. aeruginosa produce both AP and a second enzyme, elastase (E) (16, 17, 23) , we were interested in determining what effects E might have on * Corresponding author.
IFN--y. The action of the two proteases differed in at least one fundamental respect. Whereas the effect of AP on IFN-y was undiminished by the presence of human serum, the direct action of E was markedly reduced by serum components. This serum effect was primarily attributable to (X2-macroglobulin ((x2-M), a protease inhibitor found in high concentration (1 to 3 mg/ml) in human serum. Inactivation of E by x2-M appeared to result from the characteristic binding and trapping of the protease by (x2-M, and E-ax2-M complexes lacked the ability to degrade IFN-y directly. Nonetheless, E appeared to augment the effects AP had on human IFN-y, even in the presence of serum. Presented here is a mechanism for this unexpected finding that suggests that the regulation of protease effects during Pseudmonas infections may not be as simple as previously assumed.
MATERIALS AND METHODS
P. aeruginosa and Pseudomonas proteases. P. aeriuginosa GoM has been characterized previously as an AP-and E-producing strain (15, 27, 29) and was used in the present study as a representative of the majority of clinical isolates we have tested. Filtrates from this strain were prepared as previously described (15) . Crystalline preparations of Pseudomonas AP (lots 9356012 and 9442009) and E (lot 9442008) were purchased from Nagase Co., Ltd. (Tokyo, Japan) and have been characterized previously (15, 27) . Although both enzyme preparations contained lipopolysaccharide, cross contamination with the heterologous protease was less than 0.1% as judged by enzyme-linked immunosorbent assay, radioimmunoassay, or Western immunoblot assays with rabbit antisera to either protease or by stimulation of protease-specific T-cell clones (27) .
Anti-AP and anti-E antisera. Antisera to the Pseudomonas Antiviral activity was determined as described previously (15) by measuring inhibition of the cytopathic effect of vesicular stomatitis virus on the human amniotic cell line WISH. Results are expressed as units per milliliter, where 1 U of activity was defined as the amount of sample that inhibited cytopathic effect by 50% under assay conditions standardized to a National Institutes of Health IFN--y standard (Gg 23-901-530).
Polyacrylamide gel electrophoresis and Western immunoblot assays. Electrophoresis of protease-ct2-M incubation mixtures was performed on 5% native polyacrylamide minigels (Bio-Rad Laboratories, Richmond Calif.) by using the discontinuous buffer system described by Van Leuven et al. (37) Material from the region of the nonstained portion of the gel that corresponded to the electrophoretically fast migrating a2-M band was eluted at 4°C overnight in 0.1 M phosphate buffer, pH 7. This band was clearly resolvable from the region of the gel containing free E. The eluted sample was diluted in sample buffer containing SDS and 2-mercaptoethanol and then heated to 95°C for 5 min. The sample was then applied to several lanes of a 9 to 14% polyacrylamide gradient gel containing SDS, electrophoresed, and transferred to nitrocellulose. Western immunoblots were developed as described above by using either anti-a2-M or anti-E to detect the two components. Figure 1 shows the effects of purified Pseudomonas AP and E on the antiviral activity of human rINF--y. Samples of rIFN-y were incubated with the proteases, and then residual bioactivity was assessed in the WISH cell antiviral assay.
RESULTS
Both proteases reduced IFN--y bioactivity in a dose-dependent fashion. Of note was the reduction in inhibitory activity associated with E when enzyme treatment was performed in the presence of 10% human serum. Approximately 10 times more protease was required in the presence of serum to achieve the effect seen without serum. By contrast, this concentration of human serum had little effect on the activity of AP.
The serum used for this experiment was devoid of antiprotease antibodies detectable by enzyme-linked immunosorbent assay. For this reason we postulated that c02-M or a similar serum protease inhibitor might be responsible for the effect. To test this hypothesis, E was incubated with either human serum or methylamine-treated human serum for 2 h at 37°C. Methylamine is known to inactivate (x2-M by inducing a conformational change in the molecule that prevents its binding to proteases (2, 7, 35) . The mixtures were then assayed for residual protease activity or their ability to inactivate IFN--y.
Human serum (1.5 to 2%) inhibited E proteolytic activity, and methylamine treatment of the serum prevented this effect ( Fig. 2A) . Addition of as much as 22% methylaminetreated serum had no significant effect on E proteolysis of hide blue powder substrate. Similarly, the effect that E had on rIFN-y ( Fig. 2B) x 105 antiviral units per ml. A portion of the data in this figure has been published previously (15) and is presented here for comparison. Error bars indicate 1 standard deviation. The data are representative of three such experiments.
known to regulate the activity of a number of circulating proteases and does so by forming a complex with the protease, thereby sterically inhibiting its enzymatic activity. To determine whether enzymatically inactive complexes were formed between (x2-M and Pseiudoinionas E, the protease was incubated with serum or purified (x2-M and the mixtures were examined by immunoblots of native or SDSpolyacrylamide gels (Fig. 3) . Figure 3A shows the effects of treating human serum with E and monitoring the electrophoretic mobility of (x2-M with an anti-ox2-M antibody. In serum, (x2-M showed a slow electrophoretic mobility (lane 2) that corresponded to the migration of biologically active purified (x2-M (lane 1). This slow form was converted to a fast form with E treatment (lanes 3 through 6). The conversion was similar to the effect that has been reported following trypsin treatment (2, 5) or to that seen with methylamine treatment (lane 7 Consistent with these findings was the observation that both E and (x2-M could be recovered from complexes formed between the protease and serum. This was shown by incubating E with serum, electrophoresing the mixture under nondissociating conditions on a 5% polyacrylamide gel, and eluting the material that migrated in the region of the gel corresponding to the fast ot,-M band. When this eluted material was then electrophoresed on a reducing SDSpolyacrylamide gel, transferred to nitrocellulose, and developed with either anti-E or anti-<x,-M, both components were detected (data not shown).
To test the biologic effects of such complexes, samples of rIFN-y were incubated with either E or o(2-M-treated E and then inspected on immunoblots for evidence of proteolytic cleavage. Treatment of IFN-y with E led to a progressively greater fragmentation of the lymphokine as enzyme concentrations were increased (Fig. 3B) . Samples of rIFN--y treated with 10 ng of E (lane 4) were completely devoid of antiviral activity (data not shown). By contrast, E pretreated with ox2-M (lanes 5 through 7) lacked proteolytic activity in the hide blue powder assay (data not shown) and failed to cleave IFN-y, even at approximately equal molar ratios of E and IFN-y (lane 7). Viewed together, these data argue that Pseiudotinonas E, when exposed to serum U2-M, forms a complex with the macroglobulin that prevents direct proteolysis of human IFN-y by the enzyme. in Fig. 4A . The IFN-8 sample used here was a culture supernatant fluid from antigen-stimulated T cells and contained 10% human serum. As with rIFN-y, natural IFN-y was susceptible to AP at protease concentrations of 0.1 to 2 ,ug/ml but was resistant to E at similar concentrations. An unexpected finding is shown in Fig. 4B . When a suboptimal concentration of AP was used with E, the latter protease showed a potent concentration-dependent inhibitory effect, reducing the antiviral activity of the IFN--y sample more than 80% at an E concentration of 250 ng/ml. This implied that a synergistic relationship existed between the two proteases despite the presence of serum oa2-M.
On the basis of these data, one would predict that the ability of certain Pseudomonas culture filtrates to inactivate IFN--y could be reduced by pretreating the filtrates with an antiserum specific for E. The results of such an experiment are shown in Fig. 5 . Pseudomonas strain GoM produces both AP and E (27) , and filtrates prepared from the strain inactivate IFN-y bioactivity (15 Since E was shown to readily form complexes with a,-M when added to human serum and these complexes lacked proteolytic effects on IFN-y, it was of interest to determine whether E-a2-M complexes degraded IFN--y in the presence of AP. rIFN-y was susceptible to partial degradation by AP (Fig. 6, lane 2 (lanes 4 through 6). That this latter effect was due to the action of E was shown by inhibiting the effect of E-ot2-M with phosphoramidon, an active-site inhibitor of E (24) (lane 7). Therefore, E degraded IFN-y, even in the presence of a,-M, provided that AP was also present in the reaction mixture.
These results could be explained by postulating that AP inactivated ax2-M and released enzymatically active E from the complex. To test this hypothesis, E-Ox2-M complexes were exposed to AP under conditions similar to those described for Fig. 6 to determined whether release of proteolytic activity from the complex was observed. The hide blue powder assay was modified by inclusion of 25 to 50 mM EDTA, which inhibits the action of AP but not E. The inhibition of E activity caused by preincubation with u,-M was not reversed by treatment of the complex with AP (Table 1) . These results suggest that the effects of AP shown in Fig. 6 are on the substrate, rIFN-y, not on the protease inhibitor. E-a2-M complexes were prepared in the absence of EDTA by combining 2 Vg E and 60 ,g x,-M in 40 VI as described in Fig. 6 . The complexes wer-e then treated with 2 ,g of AP (37C for 1 h) in the absence of El)TA. This incubation mixture was then diluted in assay buffer-containing 25 mM EDTA.
DISCUSSION
Previously we reported that the antiviral and immunomodulatory activities of human IFN-y could be substantially reduced by exposure to Pseiudomonas AP (15) . Among the findings that led to this conclusion were the following. (i) Culture filtrates from strains that produced AP inactivated IFN-y, whereas filtrates from a protease-deficient mutant strain lacked this activity. The could be eluted from the region of the gel corresponding to fast a,-M, and this eluted material reacted with both anti-E and anti-a,-M antisera. This region of the native gel was otherwise uncontaminated by free E (i.e., free E showed a slower migration than a2-M on native gels). Third, and consistent with these biochemical findings, a,-M prevented the degradation of IFN-y by E. Taken together these data argue that a,-M forms a complex with Pseiudoinonlas E that prevents direct proteolytic degradation and inactivation of human IFN-y. Certain Pseiudomonas filtrates reduced IFN-y antiviral activity in the presence of serum, and antibody to E neutralized the effects of these filtrates. This latter finding did not at first seem consistent with the a,-M effect described above. One would have predicted that the action of E in such filtrates would have been prevented by its complexing with serum a,-M. The finding that AP and E acted synergistically, even in the presence of serum, suggested an explanation for these seemingly disparate observations. Although ot,-M inhibits the proteolytic activity of Pseuidmonas E, it may do so only for certain substrates. These include native human IFN-y. However, in the presence of AP, E-a2-M complexes appeared to further degrade rIFN--y beyond what was seen with AP alone.
Although there are several potential explanations for this phenomenon, recent studies by Borth and Teodorescu (6) suggest a likely mechanism. These investigators have reported that the ability of trypsin to inactivate interleukin-2 (IL-2) was inhibited by pretreating the enzyme with a,-M. However, trypsin -a2-M complexes were not completely devoid of proteolytic activity for IL-2 and degraded the lymphokine at a rate one-sixth that of free trypsin. They postulated that this finding reflected the fact that the relatively small substrate (15,500 daltons) gained access to the active site of the bound protease, an interpretation that is also consistent with results from similar studies with proinsulin (22) and certain synthetic peptides (1). Thus, the same mechanism may explain the action of Pseudomnonas E. We would suggest that a2-M binds E and inactivates its direct proteolytic attack on native human IFN--y. However, in the presence of AP, IFN--y is modified in such a manner that it is accessible to the enzymatic site of E within the complex and is further degraded by the second protease. Besides the partial digestion of IFN-y by AP shown on immunoblots, it is also possible that the protease promotes dissociation of the dimeric form of the lymphokine and thereby reduces its molecular dimensions. Thus, even in the presence of serum, the two proteases together yielded a much higher level of IFN--y inhibitory activity than was seen with either enzyme alone. Minor modifications of IFN-y by AP, visualized on gels, were further enhanced by E-a2-M complexes. Alternative mechanisms, including proteolytic activation of one enzyme by the other, have not as yet been entirely ruled out. However, AP and E do not show a similar synergistic effect on IFN-o, IFN-P, or casein. Likewise, we were unable to show that AP inactivates a2-M, thereby releasing active E from a preformed E-a,-M complex.
The cleavage of cytokines by bacterial proteases may provide an important means of modulating host immune responses during infections. Theander et al. (36) have reported that Pseudomonas AP and E reduced mitogen-induced T-cell proliferation by a process that appeared to involve degradation of IL-2. The protease concentrations used by these investigators, while typical of those found in stationary-phase bacterial culture filtrates, were 10 to 50 times higher than those we found to be adequate to inactivate human IFN-y (Fig. 4) . In experiments performed earlier (15) , AP at a concentration of 2 pLg/ml was sufficient to completely eliminate the antiviral activity produced in antigen-stimulated T-cell cultures, whereas IL-2-dependent proliferation of the cells was unaffected by this protease concentration. Since the experiments of Theander et al. were also performed in the presence of serum, we can only attribute their ability to inactivate IL-2 to the substantially higher protease concentrations they used.
If the effects reported here occur in vivo, the outcome for the host will depend on both the nature and quantity of proteases produced during an infection and on the concentrations of protease inhibitors found in infection sites. For example, during initial Pseuidomonas infections in the lungs (i.e., prior to extensive exudation), the pulmonary airways have very low concentrations of ot,-M. One would expect that both AP and E would be fully active under these conditions. By contrast, patients with chronic Pseudomonas pulmonary infections, as is seen in cystic fibrosis, have significant concentrations of a,-M in their lungs. Goldstein and Doring (9) have reported mean concentrations in sputum for a group of cystic fibrosis patients of 29 ,ug of oL2-M per ml and slightly elevated levels in serum averaging 4.8 mg/ml. This would be expected to result in a significant reduction in Pseudomonas E activity within the lungs even at protease concentrations of 1 ,ug/ml. The current study demonstrates that even this relationship between protease production and ao2-M concentration is not a simple one, since the concomitant production of AP by the bacterium permits the expression of E proteolytic effects on some important substrates.
